MOLECULAR ONTOGENY OF ORAL MUCOSAL RESISTANCE TO SIV

口腔粘膜对 SIV 抵抗的分子个体发生

• 批准号: 7957914
• 负责人: KATHLEEN M BRASKY
• 金额: $ 1.39万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-06 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7957914
• 关键词: Acute; Adult; Affect; Antibody Formation; Bacteria; Cercopithecidae; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Goals; Grant; Growth; Host Defense; Human; Immunologics; Infection; Inflammation; Institution; Leukocytes; Mediator of activation protein; Molecular; Mus; Oral mucous membrane structure; Pan Genus; Peptides; Primates; Proteins; Rattus; Research; Research Personnel; Resistance; Resources; SIV; Sepsis; Source; Therapeutic; Toxic effect; United States National Institutes of Health; cytokine; research study; theta-defensin

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Theta defensins are host defense peptides produced in the white blood cells of Old World monkeys (but not in chimpanzees or humans; see references below). In experiments performed in mice and rats, theta defensins facilitate clearance of bacteria in experimental infections, and also profoundly reduce the lethal effects of systemic inflammation (severe sepsis). Our long term goal is to determine the suitability of theta defensins as human therapeutics. Two adult chimpanzees will receive graded (increasing), intravenously administered doses of a naturally occurring theta-defensin RTD-1). The goal of these experiments are 1) to determine if there is any acute or subacute toxicity associated with the treatment, 2) to determine whether the administered protein elicits an antibody response in the chimpanzees, and 3) to determine whether other immunologic mediators (cytokines) are affected by the treatments.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 Theta防御素是在旧大陆猴的白色血细胞中产生的宿主防御肽（但不在黑猩猩或人类中;参见下面的参考文献）。 在小鼠和大鼠中进行的实验中，θ防御素促进实验感染中细菌的清除，并且还显著降低全身性炎症（严重脓毒症）的致死作用。 我们的长期目标是确定θ防御素作为人类治疗剂的适用性。 两只成年黑猩猩将接受分级（递增）静脉内给药剂量的天然存在的θ-防御素RTD-1。 这些实验的目的是1）确定是否存在与治疗相关的任何急性或亚急性毒性，2）确定施用的蛋白质是否在黑猩猩中激发抗体应答，和3）确定其他免疫介质（细胞因子）是否受治疗影响。